Global Leukapheresis Market Revenue Grows at a CAGR of 11.06%

Straits Research released its highly anticipated report, “Global Leukapheresis Market Size & Outlook, 2026-2034”. According to the Straits Research, the market size is valued at USD 233.76 million in 2025 and is anticipated to grow to USD 598.84 million by 2034, growing at a CAGR of 11.06% from 2026-2034.

Market Dynamics

The leukapheresis market is experiencing steady expansion driven by the rapid growth of cell and gene therapy pipelines, particularly CAR T cell therapies used in oncology and immunology. Leukapheresis serves as the foundational step for collecting patient-derived white blood cells required for downstream cell processing and manufacturing. Increasing numbers of clinical trials and regulatory approvals for autologous and allogeneic therapies are driving higher procedure volumes across hospitals, research centers, and pharmaceutical manufacturing networks. This sustained procedural demand is strengthening adoption of leukapheresis devices and consumables across both research and therapeutic applications.

Despite this growth, the market faces restraints related to procedural complexity and infrastructure intensity. Leukapheresis requires specialized equipment, trained operators, and controlled clinical environments, limiting adoption in smaller healthcare facilities. Scheduling challenges, variability in patient response, and dependency on skilled personnel restrict procedural scalability and contribute to higher operational costs, slowing wider penetration beyond established treatment centers.

The market presents strong opportunities through the decentralization of cell therapy manufacturing and expansion of regional collection centers. As therapy developers adopt distributed manufacturing models to reduce treatment timelines, demand is rising for leukapheresis capabilities embedded within local hospitals and partner sites. Integration of leukapheresis services into clinical trial networks and commercial therapy pathways is creating new revenue streams for device manufacturers and service providers, supporting long term market growth and broader geographic reach.

Key Highlights

• Product Type: Based on Product Type, the leukapheresis disposables segment is anticipated to register the fastest CAGR of 12.12% during the forecast period.
• Application: Based on Application, the therapeutics application segment is anticipated to register the fastest CAGR of 12.45% during the forecast period.
• End Use: Based on End Use, the hospitals & clinics segment dominated the market with a revenue share of 65.12% in 2025.
• Regional Insights: North America dominated the market with a revenue share of 38.34% in 2025.

Market Segments

1. By Product type (2026-2034)
   1. Leukapheresis Devices
   2. Centrifugal Devices
   3. Membrane Separators
   4. Leukapheresis Disposables
2. By Application (2026-2034)
   1. Research Application
      1. Cancer Research
      2. Immunology Research
      3. Others
   2. Therapeutics Application
      1. Hematologic Disorders
      2. Autoimmune Diseases
      3. Others
3. By End Use (2026-2034)
   1. BoldoCenters
   2. Academic & Research Institutes
   3. Pharmaceutical & Biotechnology Companies
   4. Hospitals & Clinics